Brief: Oncolytics provides initial data on combination therapy with Reolysin in multiple myeloma patients
Dec 6 (Reuters) - Oncolytics Biotech Inc:
* Oncolytics Biotech Inc collaborators present initial
results from REO 019 study in multiple myeloma combining
Reolysin, bortezomib and dexamethasone at the ash annual
meeting
* Oncolytics Biotech Inc - preliminary data suggest evidence
of activity and that treatment combination was well tolerated
Source text for Eikon: urn:newsml:reuters.com:*:nPn73fYh1a
Further company coverage: ONC.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer